76 related articles for article (PubMed ID: 1458467)
21. Tamoxifen: is it useful in the treatment of patients with metastatic melanoma?
McClay EF; McClay ME
J Clin Oncol; 1994 Mar; 12(3):617-26. PubMed ID: 8120562
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine.
Propper DJ; Braybrooke JP; Levitt NC; O'Byrne K; Christodoulos K; Han C; Talbot DC; Ganesan TS; Harris AL
Br J Cancer; 2000 Jun; 82(11):1759-63. PubMed ID: 10839287
[TBL] [Abstract][Full Text] [Related]
23. Flaxseed alone or in combination with tamoxifen inhibits MCF-7 breast tumor growth in ovariectomized athymic mice with high circulating levels of estrogen.
Chen J; Power KA; Mann J; Cheng A; Thompson LU
Exp Biol Med (Maywood); 2007 Sep; 232(8):1071-80. PubMed ID: 17720953
[TBL] [Abstract][Full Text] [Related]
24. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Serrone L; Zeuli M; Sega FM; Cognetti F
J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
[TBL] [Abstract][Full Text] [Related]
25. Trans-diammineplatinum(II): what makes it different from cis-DDP? Coordination chemistry of a neglected relative of cisplatin and its interaction with nucleic acids.
Lippert B
Met Ions Biol Syst; 1996; 33():105-41. PubMed ID: 8742842
[TBL] [Abstract][Full Text] [Related]
26. Formation and repair of 1,3-bis-(2-chloroethyl)-1-nitrosourea and cisplatin induced total genomic DNA interstrand crosslinks in human glioma cells.
Ali-Osman F; Rairkar A; Young P
Cancer Biochem Biophys; 1995 Jan; 14(4):231-41. PubMed ID: 7767897
[TBL] [Abstract][Full Text] [Related]
27. Kinetics and mechanism of the 1-beta-D-arabinofuranosylcytosine-induced potentiation of cis-diamminedichloroplatinum(II) cytotoxicity.
Vadi H; Drewinko B
Cancer Res; 1986 Mar; 46(3):1105-9. PubMed ID: 3080232
[TBL] [Abstract][Full Text] [Related]
28. Therapy for metastatic melanoma: effective combination of dacarbazine, carmustine, cisplatin and tamoxifen.
Fierro MT; Bertero M; Novelli M; Appino A; Doveil GC; Colonna S; Bernengo MG
Melanoma Res; 1993 Apr; 3(2):127-31. PubMed ID: 8518551
[TBL] [Abstract][Full Text] [Related]
29. Characterization of acquired resistance to cis-diamminedichloroplatinum (II) in BE human colon carcinoma cells.
Fram RJ; Woda BA; Wilson JM; Robichaud N
Cancer Res; 1990 Jan; 50(1):72-7. PubMed ID: 2293559
[TBL] [Abstract][Full Text] [Related]
30. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II).
Masuda H; Tanaka T; Matsuda H; Kusaba I
Cancer Res; 1990 Mar; 50(6):1863-6. PubMed ID: 2306738
[TBL] [Abstract][Full Text] [Related]
31. Effects of thaliblastine on cytotoxicity and DNA damage in drug-sensitive and -resistant rat ovarian tumor cells treated with cisplatin.
Chen G; Zeller WJ
Anticancer Res; 1993; 13(1):219-23. PubMed ID: 8476216
[TBL] [Abstract][Full Text] [Related]
32. Role of carrier ligand in platinum resistance in L1210 cells.
Gibbons GR; Page JD; Mauldin SK; Husain I; Chaney SG
Cancer Res; 1990 Oct; 50(20):6497-501. PubMed ID: 2208108
[TBL] [Abstract][Full Text] [Related]
33. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro.
Jekunen AP; Christen RD; Shalinsky DR; Howell SB
Br J Cancer; 1994 Feb; 69(2):299-306. PubMed ID: 7905279
[TBL] [Abstract][Full Text] [Related]
34. A phase I and pharmacokinetic study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma.
McClay EF; McClay ME; Jones JA; Winski PJ; Christen RD; Howell SB; Hall PD
Cancer; 1997 Mar; 79(5):1037-43. PubMed ID: 9041168
[TBL] [Abstract][Full Text] [Related]
35. Enhancement of the cytotoxicity of cisplatin by the cholecystokinin antagonist MK-329 in a human pancreatic cancer cell line.
Jamshidipour R; Pinho EB; Hom DK; Howell SB
Cancer Chemother Pharmacol; 1994; 34(6):484-90. PubMed ID: 7923559
[TBL] [Abstract][Full Text] [Related]
36. Tamoxifen modulation of carboplatin cytotoxicity in a human U-138 glioma cell line.
Mastronardi L; Farah JO; Puzzilli F; Ruggeri A
Clin Neurol Neurosurg; 1998 Jun; 100(2):89-93. PubMed ID: 9746294
[TBL] [Abstract][Full Text] [Related]
37. Modulation of cisplatin cytotoxicity by permeabilization of the plasma membrane by digitonin in vitro.
Jekunen AP; Shalinsky DR; Hom DK; Albright KD; Heath D; Howell SB
Biochem Pharmacol; 1993 May; 45(10):2079-85. PubMed ID: 8512589
[TBL] [Abstract][Full Text] [Related]
38. Modification of the effect of tamoxifen, cis-platin, DTIC, and interferon-alpha 2b on human melanoma cells in culture by a mixture of vitamins.
Prasad KN; Hernandez C; Edwards-Prasad J; Nelson J; Borus T; Robinson WA
Nutr Cancer; 1994; 22(3):233-45. PubMed ID: 7877893
[TBL] [Abstract][Full Text] [Related]
39. Effects of oncostatin M and tamoxifen on human melanoma cells.
Gibbs P; Chen Q; Robinson WA
Melanoma Res; 1998 Jun; 8(3):221-6. PubMed ID: 9664143
[TBL] [Abstract][Full Text] [Related]
40. Synergistic antiproliferative activity of tamoxifen and cisplatin on primary ovarian tumours.
Scambia G; Ranelletti FO; Benedetti Panici P; Piantelli M; De Vincenzo R; Bonanno G; Ferrandina G; Isola G; Mancuso S
Eur J Cancer; 1992; 28A(11):1885-9. PubMed ID: 1389532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
